Free Trial
→ Revealed: The Chip Stock Redefining AI as We Know It (From InvestorPlace) (Ad)

AlloVir 8/14/2024 Earnings Report

AlloVir logo
$8.60 -0.41 (-4.55%)
As of 03/28/2025
Earnings History

AlloVir EPS Results

Actual EPS
-$1.15
Consensus EPS
-$2.30
Beat/Miss
Beat by +$1.15
One Year Ago EPS
N/A

AlloVir Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

AlloVir Announcement Details

Quarter
Date
8/14/2024
Time
Before Market Opens

Conference Call Resources

Remove Ads

AlloVir Earnings Headlines

Contrasting Solid Biosciences (NASDAQ:SLDB) & AlloVir (NASDAQ:ALVR)
March 28, 2025 | americanbankingnews.com
Kalaris Announces Closing of Merger with AlloVir
March 18, 2025 | globenewswire.com
Revealed: The Chip Stock Redefining AI as We Know It
In this urgent presentation, Wall Street's so-called "AI Oracle" unveils the name of a small American tech firm poised to disrupt the $1 trillion semiconductor industry. He's the same expert who spotted Apple before the iPhone, Amazon before it dominated retail, and Google before it became a verb. Back then, Wall Street shrugged. They're doing it again—ignoring his latest prediction. But according to his research, what we've seen from AI so far is just the beginning. The real boom is still ahead.
April 1, 2025 | InvestorPlace (Ad)
AlloVir shareholders approve merger with Kalaris Therapeutics
March 14, 2025 | investing.com
AlloVir, Inc.: Kalaris and AlloVir Announce Stockholder Approval of Merger
March 13, 2025 | finanznachrichten.de
Kalaris, AlloVir announce stockholder approval of merger
March 13, 2025 | markets.businessinsider.com
See More AlloVir Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like AlloVir? Sign up for Earnings360's daily newsletter to receive timely earnings updates on AlloVir and other key companies, straight to your email.

About AlloVir

AlloVir (NASDAQ:ALVR) engages in the research, development and commercialization of off-the-shelf VST therapies to prevent and treat severe viral-associated diseases. It develops novel cell therapies with a focus on restoring natural immunity against life-threatening virus-associated diseases in patients with severely weakened immune systems. The firm's technology platforms deliver commercially scalable solutions by leveraging off-the-shelf, allogeneic, multi-virus specific T-cells targeting devastating viral pathogens for immunocompromised patients under viral attack. The company was founded by Malcolm K. Brenner, Juan F. Vera, Helen E. Heslop, Cliona M. Rooney, John R. Wilson, and Ann M. Leen in August 2013 and is headquartered in Waltham, MA.

View AlloVir Profile

More Earnings Resources from MarketBeat

Earnings Tools
Earnings By Country
Latest Articles